Login
$NRIX
$14.92 +$0.19 (1.29%) After hours

$NRIX SEC Filings

Filed On Filing
16 Nov 2026 SCHEDULE 13G/A
16 Nov 2026 SCHEDULE 13G/A
16 Nov 2026 SCHEDULE 13G/A
05 Nov 2026 SCHEDULE 13G/A
04 Nov 2026 Form 4: van Houte Hans, Chief Financial Officer

Sold 4,769 shares ($74.6K)

04 Nov 2026 Form 4: Ring Christine, Chief Legal Officer

Received 5,786 shares by exercise or conversion ($50.5K) · Sold 10,602 shares ($274K) · Sold 6,113 shares ($158K)

04 Nov 2026 144
03 Nov 2026 144
03 Nov 2026 8-K: Other Events

On November 3, 2026, Nurix Therapeutics, Inc. (the “Company”) announced that collaboration partner Sanofi S.A. (“Sanofi”) had notified the Company of its decision to discontinue the Phase 1 first-in-human clinical trial of SAR448272, an ...

02 Nov 2026 Form 4: van Houte Hans, Chief Financial Officer

Received 10,182 shares by exercise or conversion · Sold 2,834 shares ($74.5K)

02 Nov 2026 Form 4: Ring Christine, Chief Legal Officer

Received 10,182 shares by exercise or conversion · Sold 3,957 shares ($104K)

02 Nov 2026 Form 4: Hansen Gwenn, Chief Scientific Officer

Received 10,182 shares by exercise or conversion · Sold 3,957 shares ($104K) · Received 1,452 shares by exercise or conversion ($2.7K) · 1 more

02 Nov 2026 144
15 Oct 2026 Form 4: Hansen Gwenn, Chief Scientific Officer

Received 1,452 shares by exercise or conversion ($2.7K) · Sold 1,452 shares ($36.3K)

14 Oct 2026 144
14 Oct 2026 Form 4: Gregory Julia P, Director

Received 22,583 shares by exercise or conversion ($42K) · Sold 22,583 shares ($529K)

13 Oct 2026 10-Q
13 Oct 2026 8-K: Results of Operations and Financial Condition

Dosed first patient in registrational Phase 3 DAYBreak CLL-306 trial comparing bexobrutideg with pirtobrutinib in relapsed/refractory CLL/SLL

02 Oct 2026 Form 4: Ring Christine, Chief Legal Officer

Received 5,786 shares by exercise or conversion ($50.5K) · Sold 5,786 shares ($134K)

02 Oct 2026 144

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support